Clinical ResearchDiltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers: A Pilot Randomized Trial to Modify Disease Expression
Under an Elsevier user license
open archive
Key Words
cardiomyopathy
genetics
hypertrophy
translational research
treatment
trials
Abbreviations and Acronyms
CMR
cardiac magnetic resonance
E′
tissue Doppler mitral annular early relaxation velocity
HCM
hypertrophic cardiomyopathy
LGE
late gadolinium enhancement
LV
left ventricular
LVEDD
left ventricular end-diastolic diameter
LVEF
left ventricular ejection fraction
LVH
left ventricular hypertrophy
MYBPC3
cardiac myosin binding protein C gene
MYH7
cardiac β-myosin heavy chain gene
Cited by (0)
The National Institutes of Health (K23 HL078901 to Dr. Ho) funded this study but was not involved with study design or analysis. Additional support was provided to Dr. Ho by the Arthur L. Lenahan Sr. Family Foundation. Additional support to Drs. González, López, and Diez was provided by the Ministry of Economy and Competitiveness, Spain (RIC and Ramon y Cajal Program); and the European Union (HOMAGE and EU-MASCARA projects). Dr. Seidman is a founder of FCES and owns stock in Myokardia Inc., a startup company that is developing therapeutics that target the sarcomere. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.